




Docket No.: 201859US0PCT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231



ATTORNEYS AT LAW

NORMAN F. OBLON  
(703) 413-3000  
NOBLON@OBLON.COM

ROHITHA M. JAYASURIYA  
(703) 412-6247  
RJAYASURIYA@OBLON.COM

**RECEIVED**

OCT 11 2002

RE: Application Serial No.: 09/720,828  
Applicants: Jacques THEZE, et al.  
Filing Date: March 1, 2001  
For: PEPTIDES OF IL-2 AND DERIVATIVES THEREOF  
AND THEIR USE AS THERAPEUTIC AGENTS  
Group Art Unit: 1646  
Examiner: MERTZ, P.

SIR:

Attached hereto for filing are the following papers:

**TECH CENTER 1600/2900**

**RESPONSE TO RESTRICTION REQUIREMENT (5 pp.)**

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon

Registration No. 24,618



22850

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

Rohitha M. Jayasuriya  
Registration No. 50,385

DOCKET NO.: 201859US0PCT



RECEIVED

OCT 11 2002

TECH CENTER 1600/2900

#14/10  
10-16-02

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Jacques THEZE, et al.

SERIAL NO.: 09/720,828

FILED: March 1, 2001

:

: GROUP ART UNIT: 1646

:

: EXAMINER: MERTZ, Prema

FOR: PEPTIDES OF IL-2 AND DERIVATIVES THEREOF AND THEIR USE AS  
THERAPEUTIC AGENTS

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated September 10, 2002, Applicants elect, with  
traverse, Group XVI relating to SEQ ID NO:4 (improperly listed as SEQ ID NO:2), for  
further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

- Group I: Claims 1-4, drawn to an antibody which binds to a peptide of amino acid  
sequence of SEQ ID NO:2;
- Group II: Claims 1-4, drawn to an antibody which binds to a peptide of amino acid  
sequence of SEQ ID NO:4;
- Group III: Claims 5 and 10, drawn to a DNA sequence encoding a peptide of SEQ  
ID NO:2, and a vector comprising the DNA;
- Group IV: Claims 5 and 10, drawn to a DNA sequence encoding a peptide of SEQ  
ID NO:4, and a vector comprising the DNA;